Center for Coronary Artery Disease, Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, Minnesota.
School of Medicine, Pramukhswami Medical College, Karamsad, Gujarat, India.
Am J Cardiol. 2023 Apr 15;193:118-125. doi: 10.1016/j.amjcard.2023.01.044. Epub 2023 Mar 9.
Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is associated with high incidence of complications. We queried PubMed and the Cochrane Library (last search: October 26, 2022) for CTO PCI-specific periprocedural complication risk scores. We identified 8 CTO PCI-specific risk scores: (1) Angiographic coronary artery perforation (OPEN-CLEAN [Outcomes, Patient Health Status, and Efficiency iN (OPEN) Chronic Total Occlusion (CTO) Hybrid Procedures - CABG, Length (occlusion), EF <50%, Age, CalcificatioN] perforation, c-statistic 0.75): previous coronary artery bypass graft surgery, occlusion length 20 to 60 mm or ≥60 mm, left ventricular ejection fraction (LVEF) <50%, age 50 to 70 years or ≥70 years, heavy calcification. (2) Major adverse cardiovascular events (MACE) (PROGRESS-CTO complication, c-statistic 0.76): age >65 years, lesion length ≥23 mm, retrograde strategy, and (3) MACE (PROGRESS-CTO MACE, c-statistic 0.74): age ≥65 years, female gender, moderate/severe calcification, blunt/no stump, anterograde dissection and re-entry (ADR) or retrograde strategy. (4) All-cause mortality (PROGRESS-CTO mortality, c-statistic 0.80): age ≥65, moderate/severe calcification, LVEF ≤45%, ADR or retrograde strategy. (5) Perforation requiring pericardiocentesis (PROGRESS-CTO pericardiocentesis, c-statistic 0.78): age ≥65 years, moderate/severe calcification, female gender, ADR or retrograde strategy. (6) Acute myocardial infarction (PROGRESS-CTO acute myocardial infarction, c-statistic 0.72): previous coronary artery bypass graft surgery, atrial fibrillation, blunt/no stump. (7) Perforation requiring any treatment (PROGRESS-CTO perforation, c-statistic 0.74): age ≥65 years, moderate/severe calcification, blunt/no stump, ADR, or retrograde strategy. (8) Contrast-induced acute kidney injury (c-statistic 0.84): age ≥75, LVEF <40%, serum creatinine >1.5 mg/100 ml, serum albumin ≤30, 30<albumin≤40 or >40 g/L. There are 8 CTO PCI periprocedural risk scores that may facilitate risk assessment and procedural planning in patients who underwent CTO PCI.
慢性完全闭塞(CTO)经皮冠状动脉介入治疗(PCI)与高并发症发生率相关。我们在 PubMed 和 Cochrane Library 中查询了 CTO PCI 特定围手术期并发症风险评分(最后一次搜索日期:2022 年 10 月 26 日)。我们确定了 8 个 CTO PCI 特定风险评分:(1)血管造影冠状动脉穿孔(OPEN-CLEAN [结果、患者健康状况和效率 iN(OPEN)慢性完全闭塞(CTO)杂交手术-冠状动脉旁路移植术、长度(闭塞)、EF <50%、年龄、钙化 N]穿孔,C 统计量 0.75):先前的冠状动脉旁路移植术、闭塞长度 20 至 60mm 或 ≥60mm、左心室射血分数(LVEF)<50%、年龄 50 至 70 岁或≥70 岁、重度钙化。(2)主要不良心血管事件(MACE)(PROGRESS-CTO 并发症,C 统计量 0.76):年龄>65 岁、病变长度≥23mm、逆行策略,和(3)MACE(PROGRESS-CTO MACE,C 统计量 0.74):年龄≥65 岁,女性,中度/重度钙化,钝/无残端,顺行夹层和再进入(ADR)或逆行策略。(4)全因死亡率(PROGRESS-CTO 死亡率,C 统计量 0.80):年龄≥65 岁,中度/重度钙化,LVEF≤45%,ADR 或逆行策略。(5)需要心包穿刺的穿孔(PROGRESS-CTO 心包穿刺,C 统计量 0.78):年龄≥65 岁,中度/重度钙化,女性,ADR 或逆行策略。(6)急性心肌梗死(PROGRESS-CTO 急性心肌梗死,C 统计量 0.72):先前的冠状动脉旁路移植术、心房颤动、钝/无残端。(7)需要任何治疗的穿孔(PROGRESS-CTO 穿孔,C 统计量 0.74):年龄≥65 岁,中度/重度钙化,钝/无残端,ADR 或逆行策略。(8)对比剂诱导的急性肾损伤(C 统计量 0.84):年龄≥75 岁,LVEF<40%,血清肌酐>1.5mg/100ml,血清白蛋白≤30,30<白蛋白≤40 或>40g/L。有 8 个 CTO PCI 围手术期风险评分,可在接受 CTO PCI 的患者中进行风险评估和手术计划。